0 10 Activation Activation NNP 11 13 of of IN 14 21 protein protein NN 22 28 kinase kinase NNP 29 30 C C NNP 31 34 and and CC 35 44 elevation elevation NN 45 47 of of IN 48 52 cAMP cAMP NNP 53 61 interact interact VBP 62 77 synergistically synergistically RB 78 80 to to TO 81 86 raise raise VB 87 92 c-Fos c-fos NN 93 96 and and CC 97 101 AP-1 ap-1 NN 102 110 activity activity NN 111 113 in in IN 114 120 Jurkat Jurkat NNP 121 126 cells cell NNS 126 127 . . . 129 131 We we PRP 132 136 have have VBP 137 144 earlier earlier RBR 145 150 found find VBN 151 155 that that IN 156 158 in in IN 159 165 Jurkat Jurkat NNP 166 171 cells cell NNS 172 182 activation activation NN 183 185 of of IN 186 193 protein protein NN 194 200 kinase kinase NNP 201 202 C C NNP 203 204 ( ( ( 204 207 PKC PKC NNP 207 208 ) ) ) 209 217 enhances enhance VBZ 218 221 the the DT 222 228 cyclic cyclic JJ 229 238 adenosine adenosine NN 239 252 monophosphate monophosphate NN 253 254 ( ( ( 254 258 cAMP camp NN 258 259 ) ) ) 260 272 accumulation accumulation NN 273 280 induced induce VBN 281 283 by by IN 284 293 adenosine adenosine NN 294 302 receptor receptor NN 303 314 stimulation stimulation NN 315 317 or or CC 318 328 activation activation NN 329 331 of of IN 332 334 Gs Gs NNP 334 335 . . . 336 340 Here here RB 341 343 we we PRP 344 348 have have VBP 349 358 therefore therefore RB 359 367 examined examine VBN 368 371 the the DT 372 378 effect effect NN 379 381 of of IN 382 385 the the DT 386 393 phorbol phorbol NN 394 399 ester ester NN 400 403 PMA PMA NNP 404 405 ( ( ( 405 412 phorbol phorbol NN 413 425 12-myristate 12-myristate NN 426 436 13-acetate 13-acetate NN 436 437 ) ) ) 438 443 which which WDT 444 454 stimulates stimulate VBZ 455 458 PKC PKC NNP 459 462 and and CC 463 464 a a DT 465 476 combination combination NN 477 479 of of IN 480 483 the the DT 484 493 adenosine adenosine NN 494 502 receptor receptor NN 503 510 agonist agonist NN 511 515 NECA NECA NNP 516 517 ( ( ( 517 541 5’-(N-ethyl)-carboxamido 5'-(n-ethyl)-carboxamido JJ 542 551 adenosine adenosine NN 551 552 ) ) ) 553 556 and and CC 557 566 forskolin forskolin NN 567 569 to to TO 570 575 raise raise VB 576 580 cAMP camp NN 580 581 , , , 582 584 on on IN 585 588 the the DT 589 595 levels level NNS 596 598 of of IN 599 604 c-Fos c-fos NN 605 608 and and CC 609 612 Jun Jun NNP 613 616 and and CC 617 619 on on IN 620 623 the the DT 624 631 binding binding NN 632 635 and and CC 636 651 transcriptional transcriptional JJ 652 660 activity activity NN 661 663 of of IN 664 667 the the DT 668 681 transcription transcription NN 682 688 factor factor NN 688 689 , , , 690 699 activator activator NN 700 709 protein-1 protein-1 NN 710 711 ( ( ( 711 715 AP-1 ap-1 NN 715 716 ) ) ) 716 717 . . . 718 721 PMA PMA NNP 722 731 treatment treatment NN 732 738 caused cause VBD 739 740 a a DT 741 755 concentration- concentration- NN 756 759 and and CC 760 774 time-dependent time-dependent JJ 775 783 increase increase NN 784 786 in in IN 787 791 both both CC 792 797 c-Fos c-fos NN 798 801 and and CC 802 805 Jun jun NN 806 822 immunoreactivity immunoreactivity NN 823 825 in in IN 826 834 contrast contrast NN 835 837 to to TO 838 842 cAMP camp NN 843 852 elevation elevation NN 853 857 that that WDT 858 861 had have VBD 862 866 only only RB 867 868 a a DT 869 875 slight slight JJ 876 882 effect effect NN 882 883 . . . 884 888 Both both CC 889 892 PMA PMA NNP 893 896 and and CC 897 900 the the DT 901 912 combination combination NN 913 915 of of IN 916 920 NECA NECA NNP 921 924 and and CC 925 934 forskolin forskolin NN 935 940 acted act VBD 941 949 together together RB 950 956 either either CC 957 959 to to TO 960 968 increase increase VB 969 970 ( ( ( 970 975 c-Fos c-fos NN 975 976 ) ) ) 977 979 or or CC 980 988 decrease decrease NN 989 990 ( ( ( 990 993 Jun Jun NNP 993 994 ) ) ) 995 1002 protein protein NN 1003 1009 levels level NNS 1010 1012 as as RB 1013 1017 well well RB 1018 1020 as as IN 1021 1031 increasing increase VBG 1032 1036 AP-1 ap-1 NN 1037 1044 binding binding NN 1044 1045 , , , 1046 1048 as as IN 1049 1055 judged judge VBN 1056 1058 by by IN 1059 1068 gel-shift gel-shift JJ 1069 1074 assay assay NN 1074 1075 , , , 1076 1079 and and CC 1080 1084 AP-1 ap-1 NN 1085 1100 transcriptional transcriptional JJ 1101 1109 activity activity NN 1109 1110 . . . 1111 1122 Furthermore furthermore RB 1123 1128 there there EX 1129 1132 was be VBD 1133 1134 a a DT 1135 1144 clear-cut clear-cut JJ 1145 1152 synergy synergy NN 1153 1160 between between IN 1161 1164 the the DT 1165 1168 PKC PKC NNP 1169 1179 stimulator stimulator NN 1180 1183 and and CC 1184 1187 the the DT 1188 1192 cAMP camp NN 1193 1202 elevating elevate VBG 1203 1209 agents agent NNS 1209 1210 . . . 1211 1214 The the DT 1215 1222 results result NNS 1223 1234 demonstrate demonstrate VBP 1235 1239 that that IN 1240 1243 the the DT 1244 1256 simultaneous simultaneous JJ 1257 1267 activation activation NN 1268 1270 of of IN 1271 1274 PKC PKC NNP 1275 1278 and and CC 1279 1288 elevation elevation NN 1289 1291 of of IN 1292 1296 cAMP cAMP NNP 1297 1302 leads lead VBZ 1303 1305 to to TO 1306 1308 an an DT 1309 1317 enhanced enhance VBN 1318 1322 AP-1 ap-1 NN 1323 1338 transcriptional transcriptional JJ 1339 1347 activity activity NN 1348 1350 in in IN 1351 1352 a a DT 1353 1363 T-leukemia T-leukemia NNP 1364 1368 cell cell NN 1369 1373 line line NN 1373 1374 , , , 1375 1385 suggesting suggest VBG 1386 1390 that that IN 1391 1394 the the DT 1395 1405 previously previously RB 1406 1414 observed observe VBN 1415 1426 interaction interaction NN 1427 1434 between between IN 1435 1438 the the DT 1439 1447 parallel parallel JJ 1448 1454 signal signal NN 1455 1467 transduction transduction NN 1468 1476 pathways pathway NNS 1477 1480 may may MD 1481 1485 have have VB 1486 1496 functional functional JJ 1497 1509 consequences consequence NNS 1510 1512 at at IN 1513 1516 the the DT 1517 1522 level level NN 1523 1525 of of IN 1526 1530 gene gene NN 1531 1544 transcription transcription NN 1544 1545 . . .